新辅助化疗治疗乳腺癌的效果及其影响因素分析

The effect of neoadjuvant chemotherapy for breast cancer and its influencing factors

目的探讨新辅助化疗治疗乳腺癌的临床病理学特点、治疗效果及疗效影响因素。方法 78例乳腺癌患者采用ET方案进行术前新辅助化疗及疗效评估,并分析相关因素。结果术前临床疗效评价CR 21例,PR42例,SD15例,PD 0例,有效率为80.77%(63/78)。pCR15例(19.23%)。组织学分级与临床有效无关(P>0.05),但与pCR有关(P<0.05),肿瘤分级、淋巴结状态及分子亚型与临床有效及pCR有关(P<0.05)。肿瘤分期、淋巴结状态及分子亚型是乳腺癌新辅助化疗临床疗效的独立影响因子(P<0.05);组织学分级、淋巴结状态及分子亚型是乳腺癌新辅助化疗病理组织学疗效的独立影响因子(P<0.05)。结论乳腺癌新辅助化疗临床疗效较高,组织学分级、肿瘤分期、淋巴结状态及分子亚型是影响乳腺癌新辅助化疗疗效的独立因子。

Objective To investigate the clinicopathological features of neoadjuvant chemotherapy treatment for breast cancer,the treatment effect and efficacy of influencing factors. Methods All of 78 cases of breast cancer patients with ET regimen of preoperative neoadjuvant chemotherapy,preoperative efficacy evaluation,and analysis of relevant factors. Results Clinical evaluation of CR 21 cases,PR 42 cases,SD 15 eases,PD 0 cases,the effective rate was 80.77%（63/78）. pCR rate was 19.23%. Histological grade was related with clinical effectively （P 〉 0.05） ,and has related with pCR （P 〈 0.05） ,tumor grade,lymph node status,and molecular subtype,and clinically effective and pCR.Tumor stage,lymph node status and molecular subtypes the independent impact factors of breast cancer neoadjuvant chemotherapy clinical efficacy（P 〈 0.05）;histological grade,lymph node status and molecular subtypes were the independent impact factors of breast cancer neoadjuvant chemotherapy histopathological efficacy （P 〈 0.05）. Conclusion The high clinical efficacy of neoadjuvant chemotherapy,histological grade,tumor stage, lymph node status and molecular subtypes are the independent factors to affect breast cancer response to neoadjuvant chemotherapy.